- Home
- LBRX vs CCD Comparison
LBRX vs CCD Comparison
Compare LBRX & CCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LBRX | CCD |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.6M | 629.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LBRX | CCD |
|---|---|---|
| Price | $24.14 | $23.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $49.00 | N/A |
| AVG Volume (30 Days) | ★ 180.1K | 96.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.61% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.36 | $16.93 |
| 52 Week High | $24.95 | $24.68 |
Technical Indicators
Market Signals| Indicator | LBRX | CCD |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 63.71 |
| Support Level | $23.52 | $22.41 |
| Resistance Level | $24.84 | $23.18 |
| Average True Range (ATR) | 1.58 | 0.44 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 81.96 | 86.99 |
Price Performance
Historical ComparisonAbout LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
About CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.